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Introduction
There have been significant improvements in recent years
in the outcome for patients with early breast cancer. There
is little doubt that the improvements have been brought
about by a combination of earlier detection in asympto-
matic patients and more aggressive use of anticancer
therapies in the absence of clinically evident disease.
In trying to understand why some cancers metastasise to
some organs and not others, students are often taught the
‘seed and soil’ hypothesis of metastatic cancer. This sug-
gests that the ability of cells to survive and grow to
produce clinically detectable metastases distant to the
site of the primary tumour is a reflection of the properties
of both the host tissue/organ and the metastatic tumour
cells. However, the majority of successful anticancer ther-
apies to date have in reality only been directed at the seed
(the postulated micrometastases that determine the ulti-
mate outcome for our patients) or, in the case of
endocrine therapies, the endocrinology of the whole
patient. Trevor Powles and colleagues recently presented
their study about clodronate in the adjuvant setting [1],
reporting an overall survival advantage to be gained by
administration of a therapy designed to alter the properties
of only one organ in the patient: bone, the ‘soil’ of any
future bone metastases. This intriguing approach and its
results present us with the question of whether it is time
for a change in clinical practice.
Targeting soil and seed
Powles and colleagues [1] are to be congratulated for
taking the paradigm of adjuvant therapy one step further in
that, by administering 2 years’ therapy with an oral bisphos-
phonate, they attempted to change the environment in
which bone micrometastases persist in order to improve
patients’ outcome. As such, their study is a milestone that
may have profound influence upon future approaches to
the treatment of early disease.
Bisphosphonates, among other agents, inhibit osteoclasts
[2,3] and thus can potentially disrupt the vicious cycle that
probably occurs in the vicinity of bone micrometastases:
tumour cells stimulate the osteoclasts, which leads to
increased bone resorption and the release of growth
factors that in turn stimulate the growth of the metastases.
Giving a bisphosphonate in combination with a systemic
anticancer therapy, as was the case for 95% of the
patients in the experimental arm, is the epitome of target-
ing soil and seed at one and the same time. It also exploits
the potential synergy with traditional anticancer therapies
[4,5] and the possible direct antitumour effects of bisphos-
phonates [6–8]. The study by Powles and colleagues [1]
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suggests that combination therapy is a better strategy
than just targeting the seed with systemic anticancer
therapy alone.
Trial summary
Powles and colleagues’ report in the August 2002 issue
of the Journal of Clinical Oncology [1] presents the first
results from a double-blind randomised trial of 2 years’ oral
clodronate or placebo in 1069 women with early breast
cancer. Patients were expected to have their surgery,
radiotherapy, and adjuvant systemic therapy according to
local protocols. It was not clear whether any stratification
criteria were applied, and the survival analyses were not
controlled for the adjuvant systemic therapy given.
The primary end-point was relapse in bone, and there was
a non-significant reduction (63 versus 80 patients,
P=0.127). Similarly there were no significant differences
in the incidence of non-bone metastases (112 versus 128,
P=0.257). There were, however, significantly fewer
patients developing bone metastases during the time they
took clodronate/placebo (12 versus 28, P=0.016), and
there was a significant improvement in overall survival (98
versus 129 deaths, P=0.047) [1].
Trial results
Although the primary end-point was not statistically signifi-
cant, there were two positive secondary end-points whose
possible clinical implications must be considered. First,
during the 2 years of therapy, the group of patients who
took the oral bisphosphonate clodronate in addition to
their standard therapy experienced significantly fewer
bone metastases. This advantage appeared to be lost
during the subsequent follow-up period, however, with as
many patients who had taken bisphosphonates develop-
ing bone metastases as those who had not.
Second, an overall survival advantage was noted
(P<0.05) that began to appear beyond the 2 years of
therapy. As Professor Mundy pointed out in the editorial
that accompanied Powles and colleagues’ article in the
Journal of Clinical Oncology [9], not only are the
observed effects consistent with data from model systems
[10] but, even without hypothesising an effect on non-
osseous disease, it is very plausible that the decrease in
bone metastases could lead to the overall survival advan-
tage.
Similar studies
This is not the first study to use adjuvant oral bisphospho-
nates with the aim to improve the outcome for women with
early breast cancer. Two previous smaller studies showed
exactly opposite effects from one another using the same
drug. In the study reported by Ingo Diel and colleagues
[11], 302 women who were found to have breast cancer
cells in bone marrow aspirates were randomised to take
oral clodronate for 2 years or not. Although a clear benefit
has been reported in terms of disease-free survival, the
benefit in non-osseous disease reported initially was not
seen on longer follow-up [12]. Furthermore, since this
study only included women with evidence of
micrometastatic breast cancer in the bone marrow, it is
not quite the same as a normal adjuvant study where
patients are enrolled on the basis of having no evidence of
metastases.
In contrast, a similarly modestly sized study by Saarto and
colleagues reported no benefit whatsoever in the inci-
dence of bone metastases with 2 years’ adjuvant oral clo-
dronate in women with node-positive breast cancer [13].
They even reported a poorer outcome for non-osseous
disease that resulted in a worse survival in the women
taking clodronate. There are, however, concerns about
significant imbalances in the patients in the two arms that
could have led to this paradoxical result.
Implications for practice
Does this mean that all patients with early breast cancer
should now receive a bisphosphonate (and perhaps even
clodronate in particular) for 2 years over and above their
routine therapy? I believe not, despite my enthusiasm for
the study by Powles and colleagues [1], and the reasons
lie within the study’s detail.
A randomised clinical trial of an intervention, such as this,
contributes to our understanding but can rarely alone
change it, unless the benefit of the intervention is
absolutely clear. There is no doubt that the benefit
reported in the clodronate-treated group is consistent with
the previous positive study by Diel and colleagues [11]
(but not that of the apparently less-well balanced Saarto
and colleagues’ trial [13]), as well as our hypotheses and
experimental data regarding how a bisphosphonate could
benefit patients at risk of developing bone metastases
[14,15]. But the null hypothesis of any study is that the
observed differences could occur by chance, due to het-
erogeneity in factors affecting the natural history of the
underlying disease. In deciding whether the result of a
clinical trial such as this should influence standard
therapy, the clinician has to determine whether the differ-
ences observed between the two arms are due to the
therapeutic intervention, or to random imbalances in the
many factors that influence patient outcome in early breast
cancer.
Using traditional statistical methodology, the difference in
the overall bone metastases-free survival curves in the
Powles and colleagues’ trial [1] is not statistically signifi-
cantly different — with P>0.1, implying a greater than one
in 10 chance of the same difference occurring without any
therapeutic intervention. Similarly, the difference in the
overall survival curves only just reaches statistical signifi-298
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cance at the 5% level, implying that this could also have
arisen without any intervention with a chance of about one
in 20. Given that at least three statistical analyses were
performed (disease free, bone metastases free and overall
survival), then if one had applied the Bonferroni correction
as would be conventional for multiple primary end-points,
this would reduce the level of significance to less than
0.02. The overall survival curves would thus no longer be
considered statistically significantly different, although
there would remain a suggestive trend.
Although the traditional prognostic factors are well bal-
anced, the oestrogen receptor status is unknown in almost
one-third of patients. The reader is therefore not entirely
sure how well balanced the arms are for this important
factor, which relates to outcome, to benefit of adjuvant
tamoxifen, and to risk of developing bone metastases. Fur-
thermore, there is also evidence for small differences in
the numbers of patients in the two arms who did not
receive standard breast cancer therapy, such as the addi-
tional seven patients in the control arm who had no local
therapy at all. There are also small differences in the
numbers of patients receiving various chemotherapy regi-
mens. Whether these differences relate to local practices
or to the characteristics of the patients’ tumours is of no
importance: what does matter is that they indicate the
possibility of different prognostic groups within the two
arms of the trial.
These differences may seem trivial until one realises that
the difference in the bone metastases-free survival curves
are created by only 16 fewer patients developing bone
metastases during the first 2 years of the trial, with no dif-
ference in the numbers beyond then. Furthermore, 17
more patients in the control arm developed visceral metas-
tases, and the shape of the overall survival curves are very
similar to those of the non-osseous metastases-free
curves (which again do not appear to be statistically signif-
icantly different). In complete contrast to the pattern of
emergence of the bone metastases, however, the differ-
ence in the proportion of patients developing non-osseous
metastases only appeared after patients had stopped the
clodronate/placebo medication.
These observations suggest two possible hypotheses: (1)
either clodronate does have a small effect on the rate of
appearance of non-osseous disease, consistent with the
first report [11], but not the later report [12], of the Diel
and colleagues’ study; or (2) there was an imbalance in
the as yet undefined factors that determine the appear-
ance of visceral metastases and their poorer outcome.
Since the data presented do not allow us to confirm either
of these two hypotheses, the Powles and colleagues’
report alone does not provide sufficient grounds for a
change in practice. It is also worth noting that the clo-
dronate arm had only two-thirds of the number of non-
breast cancer deaths seen in the control arm: either a
further reflection of the heterogeneity in patients even in a
study of this size, or perhaps evidence for a survival
benefit unrelated to any effect on breast cancer!
Conclusions
Powles and colleagues clearly present an important study,
which may well indicate the direction of future research
and practice. If longer follow-up affords an even greater
bone metastases-free survival advantage to the clodronate
group, a change in practice could be considered. Mean-
while, studies are being planned with more potent bispho-
sphonates. If the studies show similar or greater benefits,
then the case for the use of this class of drugs in routine




The author is grateful to an anonymous reviewer whose comments
have, it is hoped, made this article more accessible to non-clinicians.
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